Oric Pharmaceuticals Inc (ORIC) FinancialsORICOric Pharmaceuticals Inc

Evaluating the bottom line, ORIC Pharmaceuticals, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -39.80%, provide a clear picture of how effectively ORIC converts its operational activities into shareholder value.

In the context of the broader market, ORIC competes directly with industry leaders such as LBRX and DMRA. With a market capitalization of $1.32B, it holds a leading position in the sector. When comparing efficiency, ORIC's gross margin of N/A stands against LBRX's N/A and DMRA's N/A. Such benchmarking helps identify whether ORIC Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Oric Pharmaceuticals has reported a net loss of $41.49 million in Q2 2026, resulting in an EPS of -$0.38, which missed expectations by $0.02. The company has a current ratio of 13.19, indicating strong liquidity, but it is still facing significant operational losses.